, 22 , 4104-4110, doi: Strohkamp, S., Gemoll, T., Humborg, S., Hartwig, S., Lehr, S., Freitag-Wolf, S., Becker, S., Franzn, B., Pries, R., Wollenberg, B., Roblick, U
For those considering Cerebrolysin, key limitations include: no prevention trials have been conducted (all studies in existing disease), optimal dosing remains uncertain (higher doses may actually be less effective), batch-to-batch variability in peptide content, and the inconvenience of repeated IV infusion cycles
If your symptoms point to a more complex issue, we are equipped to evaluate further and arrange appropriate referrals
Neurological, psychomotor, cardiovascular, ocular and hepatic disorders